-
公开(公告)号：KR101144563B1
公开(公告)日：2012-05-11
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
-
12.发明公开유럽종 포도의 씨 추출물 및 레바미피드를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물 有权用于预防或治疗包含VITIS VINIFERA PIP提取物和雷巴米地的含盐酸盐的药物组合物
公开(公告)号：KR1020120032649A
公开(公告)日：2012-04-06
申请号：KR1020100094091
申请日：2010-09-29
Applicant: 한림제약(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing rebamipide and Vitis vinifera seed extract is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rebamipide and Vitis vinifera seed extract. The pharmaceutical composition is orally administered in the form of a tablet or capsule. The dosage of rebamipide is 0.3 mg/kg a day.
Abstract translation: 目的：提供含有瑞巴派特和葡萄种子提取物的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有瑞巴派特和葡萄籽种子提取物。 药物组合物以片剂或胶囊的形式口服给药。 瑞巴派特的剂量为每天0.3mg / kg。
-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
公开(公告)号：KR1020110121086A
公开(公告)日：2011-11-07
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
CPC classification number: A01K67/027 , A01K2207/25 , A01K2227/105 , A01K2267/03
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
Abstract translation: 目的：提供关节炎小鼠动物模型及其制造方法，以更严重地关注关节炎的症状。 构成：关节炎小鼠动物模型的制造方法包括：通过向小鼠喂食高热量饲料来诱导肥胖的步骤; 以及通过在小鼠中服用胶原来引起关节炎的步骤。 在胶原蛋白传代步骤中，首先接种胶原，将小鼠育种一段指定的时间，然后接种胶原蛋白。 在第一次接种中，施用胶原蛋白和完全弗氏佐剂的混合溶液。 在第二次接种中，施用胶原蛋白和不完全弗氏佐剂的混合溶液。
-
公开(公告)号：KR1020110021016A
公开(公告)日：2011-03-04
申请号：KR1020090078547
申请日：2009-08-25
Applicant: 가톨릭대학교 산학협력단 , 한림제약(주)
IPC: A61K31/4704 , A61P19/02 , A61K9/20 , A61K9/48
CPC classification number: A61K31/4704
Abstract: PURPOSE: A pharmaceutical composition containing rabamipide and pharmaceutically acceptable carrier is provided to prevent or treat rheumatoid arthritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatoid arthritis contains rabamipid and pharmaceutically acceptable carrier. The pharmaceutical composition is used for oral administration. The pharmaceutical composition is formed in oral solid dosage. The pharmaceutical composition has rabamipid formulated in 0.5-50 mg/kg of unit dosage form.
Abstract translation: 目的：提供含有拉巴米特和药学上可接受的载体的药物组合物，以预防或治疗类风湿性关节炎。 构成：用于预防或治疗类风湿性关节炎的药物组合物含有拉帕米特和药学上可接受的载体。 药物组合物用于口服给药。 药物组合物以口服固体剂量形成。 药物组合物具有配制在0.5-50mg / kg单位剂型中的拉巴米特。
-
Patent Agency Ranking16.发明授权ＥＧＣＧ를 유효성분으로 함유하는 쇼그렌 증후군, 베체트 증후군, 강직성척추염 또는 루프스의 예방 또는 치료용 조성물 有权用于预防或治疗干燥综合征的组合物Behcet综合征强直性脊柱炎或包含EGCG作为活性成分的系统性红斑狼疮
公开(公告)号：KR101705361B1
公开(公告)日：2017-02-10
申请号：KR1020100048052
申请日：2010-05-24
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/353 , A61K31/355 , A23L1/30
Abstract: 본발명은 EGCG(epigallocatechin gallate)를유효성분으로함유하는약학적조성물에관한것으로서, 보다구체적으로는 EGCG를유효성분으로함유하는쇼그렌증후군, 베체트증후군, 강직성척추염또는루프스의예방또는치료용조성물, EGCG를이용한미분화 T 세포의 Th17 세포로의분화를감소또는억제하는방법, 조절 T 세포를활성화시키는방법, 면역억제용조성물및 기능성건강식품에관한것이다. 본발명에따른 EGCG 화합물은염증성사이토카인을생성및 분비하는세포독성 Th17 세포의분화를억제하는효과가우수하고, 비정상적으로활성화된면역세포의기능을억제하고염증반응을제어하는특성을갖는면역조절 T 세포(Treg)는활성화시키는효과가우수하므로면역반응의조절이상으로유발되는쇼그렌증후군, 베체트증후군, 강직성척추염또는루프스를예방또는치료할수 있는약학적조성물및 면역억제제로사용할수 있으며, 나아가이러한질환들을개선및 예방할수 있는식품용조성물로도사용될수 있는효과가있다.
Abstract translation: 目的：提供含有EGCG（表没食子儿茶素没食子酸酯）的药物组合物，以抑制细胞毒Th17细胞的分化，并预防或治疗干燥综合征，白塞综合征或狼疮。 构成：用于预防或治疗干燥综合征，白塞综合征或狼疮的组合物含有EGCG（表没食子儿茶素没食子酸酯）化合物或其盐作为活性成分。 EGCG抑制或减少未分化T细胞分化为Th17细胞。 用于激活调节性T细胞的方法包括在体外将T细胞（Treg）处理EGCG化合物或其盐的步骤。 用于治疗或预防干燥综合征，白塞综合征或狼疮的功能性食物含有EGCG化合物或其盐作为活性成分。 用于抑制免疫的组合物含有EGCG化合物或其盐作为活性成分。
-
公开(公告)号：KR101317492B1
公开(公告)日：2013-10-15
申请号：KR1020110049894
申请日：2011-05-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/166 , A61K31/16 , A61K31/06 , A61P21/00
Abstract: 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 AG490 화합물은 염증성 사이토카인을 생성 및 분비하는 병인성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)의 활성을 증진시키는 효과가 우수하면서도 p53 유전자의 발현을 촉진시키므로 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용할 수 있다.
-
18.发明授权
-
公开(公告)号：KR1020120026208A
公开(公告)日：2012-03-19
申请号：KR1020100088295
申请日：2010-09-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/015 , A61P35/00
Abstract: PURPOSE: A composition containing STA-21 for preventing or treating cancer or immune diseases is provided to suppress cytotoxic Th17 cell differentiation and to control inflammation. CONSTITUTION: A composition for preventing and treating cancer or immune diseases contains STA-21 compounds of chemical formula 1 or pharmacetuically acceptable salt thereof as an active ingredient. The STA-21 promotes or increases activation or amplification of regulatory T cells. A method for reducing or suppressing differentiation of undifferentiated T cells into Th17 cells in vitro comprises a step of treating STA-21 compounds or pharmaceutically acceptable salt thereof to the undifferentiated cells. A composition for anticancer or immunodepression contains STA-21 compounds or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的STA-21的组合物，以抑制细胞毒性Th17细胞分化并控制炎症。 构成：用于预防和治疗癌症或免疫疾病的组合物含有化学式1的STA-21化合物或其药学上可接受的盐作为活性成分。 STA-21促进或增加调节性T细胞的活化或扩增。 未分化T细胞在体外分化为Th17细胞的方法包括将STA-21化合物或其药学上可接受的盐处理至未分化细胞的步骤。 用于抗癌或免疫抑制的组合物含有STA-21化合物或其药学上可接受的盐作为活性成分。
-
20.发明公开ＥＧＣＧ를 유효성분으로 함유하는 쇼그렌 증후군, 베체트 증후군, 강직성척추염 또는 루프스의 예방 또는 치료용 조성물 有权用于预防或治疗SJOGREN综合征，BEHCET综合征，包括作为活性成分的EGCG的神经系统性红斑狼疮或系统性红斑狼疮的组合物
公开(公告)号：KR1020110128542A
公开(公告)日：2011-11-30
申请号：KR1020100048052
申请日：2010-05-24
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/353 , A61K31/355 , A23L1/30
CPC classification number: A61K31/353 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K31/355
Abstract: PURPOSE: A pharmaceutical composition containing EGCG(epigallocatechin gallate) is provided to suppress differentiation of cytotoxic Th17 cells and to prevent or treat Sjogren syndrome, Behcet syndrome, or lupus. CONSTITUTION: A composition for preventing or treating Sjogren syndrome, Behcet syndrome, or lupus contains EGCG(epigallocatechin gallate) compound or salt thereof as an active ingredient. The EGCG suppresses or reduces differentiation of undifferentiated T cells into Th17 cells. A method for activating regulatory T cells comprises a step of treating the EGCG compounds or salt thereof to the T cells(Treg) in vitro. A functional food for treating or preventing Sjogren syndrome, Behcet syndrome, or lupus contains the EGCG compound or salt thereof as an active ingredient. A composition for suppressing immunity contains the EGCG compounds or salt thereof as an active ingredient.
Abstract translation: 目的：提供含有EGCG（表没食子儿茶素没食子酸酯）的药物组合物，以抑制细胞毒Th17细胞的分化，并预防或治疗干燥综合征，白塞综合征或狼疮。 构成：用于预防或治疗干燥综合征，白塞综合征或狼疮的组合物含有EGCG（表没食子儿茶素没食子酸酯）化合物或其盐作为活性成分。 EGCG抑制或减少未分化T细胞分化为Th17细胞。 用于激活调节性T细胞的方法包括在体外将T细胞（Treg）处理EGCG化合物或其盐的步骤。 用于治疗或预防干燥综合征，白塞综合征或狼疮的功能性食物含有EGCG化合物或其盐作为活性成分。 用于抑制免疫的组合物含有EGCG化合物或其盐作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.026 seconds)
